NASDAQLPCN
Year
View
Form | Description | Date | Format |
---|---|---|---|
SC 13G | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions | Nov 22, 2019 | ![]() ![]() ![]() ![]() |
We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technology.
Form | Description | Date | Format |
---|---|---|---|
SC 13G | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions | Nov 22, 2019 | ![]() ![]() ![]() ![]() |